Difference between revisions of "Enzalutamide"

From Libre Pathology
Jump to navigation Jump to search
Line 1: Line 1:
'''Enzalutamide''' is an antrogen receptor antagonist used to treat [[prostate cancer]].<ref name=pmid23887973>{{Cite journal  | last1 = Mitsiades | first1 = N. | title = A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer. | journal = Cancer Res | volume = 73 | issue = 15 | pages = 4599-605 | month = Aug | year = 2013 | doi = 10.1158/0008-5472.CAN-12-4414 | PMID = 23887973 }}</ref>
'''Enzalutamide''' is an [[antrogen receptor]] antagonist used to treat [[prostate cancer]].<ref name=pmid23887973>{{Cite journal  | last1 = Mitsiades | first1 = N. | title = A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer. | journal = Cancer Res | volume = 73 | issue = 15 | pages = 4599-605 | month = Aug | year = 2013 | doi = 10.1158/0008-5472.CAN-12-4414 | PMID = 23887973 }}</ref>


==See also==
==See also==

Revision as of 13:08, 18 March 2019

Enzalutamide is an antrogen receptor antagonist used to treat prostate cancer.[1]

See also

References

  1. Mitsiades, N. (Aug 2013). "A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer.". Cancer Res 73 (15): 4599-605. doi:10.1158/0008-5472.CAN-12-4414. PMID 23887973.